Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Faslodex
Pharma
AZ's first-in-class breast cancer approval marred by restriction
AstraZeneca's Truqap is the first AKT inhibitor to win an FDA nod. But a biomarker restriction from the FDA came as a surprise.
Angus Liu
Nov 17, 2023 11:02am
Novartis' Kisqali nabs restricted NICE backing
Jul 17, 2019 10:12am
AZ’s Faslodex hit with U.S. generic on heels of blockbuster year
May 31, 2019 11:10am
NICE shoots down AZ's Faslodex, citing dearth of data
Sep 1, 2017 11:42am
AZ oldie Faslodex nets another breast cancer approval
Aug 29, 2017 12:26pm
